News
China NMPA approves InnoCare Pharma’s orelabrutinib for first-line treatment of patients with CLL/SLL: Beijing Monday, April 28, 2025, 12:00 Hrs [IST] InnoCare Pharma, a leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback